Podcasts about annual meetings

This week, we welcome Cornell Winston (current President of the American Association of Law Libraries) and Jenny Silbiger (President‑Elect). Speaking from sunny San Diego and O‘ahu's courthouse halls, the duo joins the show to preview AALL's 2025 Annual Meeting in Portland, Oregon—and to talk candidly about the challenges and opportunities facing the legal‑information profession during a time of rapid technological and political flux.Cornell and Jenny explain why open communication has become a strategic imperative for AALL. Although board books have long been public, they are doubling down on proactive updates—through e‑briefings, “Know‑It‑AALL” newsletters, and 80‑plus committee channels—because members crave clarity when the profession feels under siege. Their message is simple: phone numbers and inboxes are open; no question is off‑limits. The leaders frame transparency not as a defensive posture, but as an invitation to pull every member into the conversation and decision‑making process.The discussion then turns to the vacant Government Relations role—often seen as AALL's front line in Washington. Cornell reassures listeners that, despite the hiring gap, advocacy has never left the stage: the Government Relations Committee partners with ALA and other allies, tracks executive‑order whiplash, and issues public statements on IMLS funding or Library of Congress appointments. While lobby dynamics have shifted since COVID‑era restrictions, AALL continues to file comments, weigh amicus briefs, and equip members to speak up in their own jurisdictions until the position is refilled.Next, the hosts probe changes to the volunteer pipeline. Under the new process, virtually every member who raises a hand gets a seat—whether on a jury, committee, or the coveted Annual Meeting Program Committee. Headquarters now monitors overlapping appointments to spread opportunities and ensure early‑career librarians experience the career‑shaping mentorship Greg once received from the late Bob Oakley. Jenny underscores that engagement options range from micro‑tasks to multi‑year leadership roles, accommodating both time‑pressed newcomers and seasoned veterans.Turning to the July 19‑22 conference itself, Cornell shares upbeat registration numbers, hotel tips, and—importantly—news of no late‑registration fee increase. Portland's light‑rail pass, tax‑free shopping, and Nike/Columbia/Adidas discounts sweeten the trip, but the intellectual draw is formidable: 65‑plus programs, four pre‑conference workshops, and a cross‑pollinated AI track that unites academic and private‑sector librarians. Keynote speaker Roosevelt Weeks, renowned for transforming Austin Public Library into a nationally acclaimed, radically welcoming space, will challenge attendees to double down on access and inclusion.Asked for their “biggest challenge” predictions, Jenny cites the breakneck pace of AI and the resulting imperative to preserve integrity in an era of deepfakes and data deluge. Cornell echoes the warning: librarians must remain society's trusted validators and proclaim that expertise without apology. As the gavel passes in Portland, Jenny's presidential agenda crystallizes around three goals—meeting members where they are, converting dialogue into strategic action, and leaving the profession stronger for the next generation. Whether you are a long‑time AALL stalwart or a first‑time volunteer, this episode is a reminder that the future of legal information will be shaped by those who show up, speak up, and keep the channels open.Listen on mobile platforms:  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Apple Podcasts⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ |  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠[Special Thanks to ⁠Legal Technology Hub⁠ for their sponsoring this episode.] Blue Sky: ⁠⁠@geeklawblog.com⁠⁠ ⁠⁠@marlgeb⁠⁠⁠⁠⁠⁠⁠Email: geekinreviewpodcast@gmail.comMusic: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Jerry David DeCicca⁠⁠⁠⁠⁠⁠⁠⁠⁠ Transcript

This week's episode will be focusing on exciting data in GU presented at the 2025 ASCO Annual Meeting in prostate (including prognostication of PSA response in mCSPC, AMPLITUDE - PARPi in mCSPC), RCC (including updates in KN-564, CM-214 and PDIGREE), and finally bladder CA (with updates in NIAGARA and EV-302) among others. 

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Wendi Hulett, Chief Nursing Officer at Lincoln County Medical Center – Presbyterian Healthcare Services. She discusses how her team drastically reduced nurse turnover through a rapid hire process and shares insights on navigating workforce expectations and the evolving role of AI in nursing.

Stakeholders from across the healthcare industry, including members of Congress, the US Food and Drug Administration, and the Center for Medicare and Medicaid Services, recently convened in Washington D.C. for the Medical Device Manufacturers Association (MDMA) Annual Meeting. In this episode of Connected With Latham, Washington, D.C. partners Chris Schott, Nate Beaton, and Bill McConagha, and associate Danny Machado share their key takeaways from the meeting, including compliance hot topics and what the industry can expect in terms of regulatory enforcement in 2025.   This podcast is provided as a service of Latham & Watkins LLP. Listening to this podcast does not create an attorney client relationship between you and Latham & Watkins LLP, and you should not send confidential information to Latham & Watkins LLP. While we make every effort to assure that the content of this podcast is accurate, comprehensive, and current, we do not warrant or guarantee any of those things and you may not rely on this podcast as a substitute for legal research and/or consulting a qualified attorney. Listening to this podcast is not a substitute for engaging a lawyer to advise on your individual needs. Should you require legal advice on the issues covered in this podcast, please consult a qualified attorney. Under New York's Code of Professional Responsibility, portions of this communication contain attorney advertising. Prior results do not guarantee a similar outcome. Results depend upon a variety of factors unique to each representation. Please direct all inquiries regarding the conduct of Latham and Watkins attorneys under New York's Disciplinary Rules to Latham & Watkins LLP, 1271 Avenue of the Americas, New York, NY 10020, Phone: 1.212.906.1200

Riding Shotgun With Charlie  Pit Stop Brandon Maddox I was able to get some time with Brandon Maddox from  ⁨@SilencerCentral⁩  at  ⁨@NRA⁩  Annual Meeting's Voices of the Second Amendment. Check it out! Silencer Central Website https://www.silencercentral.com/ X https://x.com/Silencercentral Instagram https://www.instagram.com/silencercentral Facebook https://www.facebook.com/SilencerCentral/ US Law Shield Legal Defense for Self Defense. Use "RSWC" as the discount code and get 2 months for free! https://www.uslawshield.com/ Patriot Mobile Use this link and get one month for free! https://patriotmobile.com/partners/rswc  

How do we fix the health care system for doctors? What policies does the American Medical Association support? What's going to happen to Medicare? Our guest is Todd Askew, senior vice president of Advocacy at the American Medical Association. AMA CXO Todd Unger hosts.

Municipal Association Executive Director Todd Glover and Chief Operating Officer Jake Broom preview the 2025 Annual Meeting, taking place on Hilton Head Island July 16 – 20. It will have sessions focused on civility and communication in local government, attracting remote workers, gun violence reduction, competing for commercial development, and the new IMPACT Fund grant, among others. Learn more: www.masc.sc/2025-annual-meeting

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Heather Resseger, Senior Vice President, Chief Hospital Operations Officer and Chief Nursing Officer at NorthBay Health. She discusses her organization's Magnet recertification, workforce engagement strategies, and the critical need to address behavioral health as a core component of improving care delivery.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Lynne Fiscus, President and Chief Executive Officer of UNC Physicians Network. She shares insights on building a sustainable clinical workforce through initiatives like the O2 onboarding and optimization team, and highlights how UNC Health is prioritizing flexibility to reduce burnout and improve care delivery.

Send us a textJoin host Dr. Jeff Mullin as he sits down with Dr. Jennifer Bauer, co-chair of the 60th Annual Meeting in Charlotte, North Carolina, USA. Tune in as they explore the highlights of the educational and scientific program, and preview exciting events like the Welcome Reception!The Annual Meeting is a forum for the realization of the Society's mission and goals, the improvement of patient care for those with spinal deformities. A Faculty-led Pre-Meeting Course and abstract papers will be presented on an array of topics, including adolescent idiopathic scoliosis, growing spine, kyphosis, adult deformity, minimally invasive surgery, machine learning, and mental health considerations.*The Scoliosis Research Society (SRS) podcast is aimed at delivering the most current and trusted information to clinicians that care for patients with scoliosis and other spinal conditions. From news in the world of spinal conditions, to discussions with thought leaders in the field, we aim to provide up-to-date, quality information that will impact the daily practice of spinal conditions.

Buffalo, NY — June 4, 2025 — The Longevity & Aging Series has been honored with the Silver Award for “Excellence in Video/Film” at the inaugural EPIC Awards celebration on May 29, 2025, during the Society for Scholarly Publishing (SSP) 47th Annual Meeting in Baltimore, Maryland. The EPIC Awards recognize the achievements of those who are advancing scholarly publishing through creativity, collaboration, and cutting-edge innovation. The Longevity & Aging Series, hosted by Aging (Aging-US) Editorial Board member Dr. Evgeniy Galimov, stood out for its impactful storytelling, production quality, and commitment to advancing understanding in the field of aging research. The Longevity & Aging Series brings together leading experts to discuss the latest developments in the biology of aging, healthy longevity, and interventions to improve healthspan. Now in its third season, the series is a trusted resource for scientists, clinicians, and the broader public interested in the future of aging research. For more information about the Aging (Aging-US) Longevity & Aging Series and to view the award-winning videos, please visit our show page or YouTube channel. If you are interested in becoming a guest or would like to know more about the series, please email us at media@impactjournals.com. Longevity & Aging Series Show Page - https://www.aging-us.com/longevity Aging-US YouTube Channel - https://www.youtube.com/@AgingJournal To learn more about the journal, please visit our website at https://www.Aging-US.com​​ and connect with us on social media at: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ LinkedIn - https://www.linkedin.com/company/aging/ Bluesky - https://bsky.app/profile/aging-us.bsky.social Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc

Featuring perspectives from Dr Daniel George, Dr Leonard G Gomella and Dr Evan Y Yu, moderated by Dr George, including the following topics: Introduction (0:00) Current Treatment Landscape for Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Gomella (3:42) Clinical Implications of and Appropriate Strategies to Identify PTEN Deficiency in Prostate Cancer — Dr Yu (35:37) Emerging Role of AKT Inhibition for mHSPC — Dr George (1:06:18) CME information and select publications

Top headlines for Tuesday, June 3, 2025In this episode, we explore the chilling targeted terror attack on a group advocating for the release of Israeli hostages in Gaza, as detailed by the FBI. Then, we discuss the controversy surrounding a Kennedy Center official allegedly fired over conservative Christian beliefs, with insights from a source close to Richard Grenell. Finally, we examine the social media backlash against Sesame Street over its celebration of Pride Month, amidst ongoing accusations of grooming. 00:11 Boulder terror attack suspect used flamethrower, set 8 on fire01:16 Truett McConnell University responds to abuse allegations02:09 Trump envoy 'didn't know' fired Kennedy Center official: source03:16 Pro-life groups celebrate Vermont amending 'discriminatory' law04:04 Sesame Street stokes backlash for promoting pride month05:01 5 important SBC Annual Meeting proposed resolutions05:46 Brandon Lake sweeps K-LOVE Fan AwardsSubscribe to this PodcastApple PodcastsSpotifyGoogle PodcastsOvercastFollow Us on Social Media@ChristianPost on TwitterChristian Post on Facebook@ChristianPostIntl on InstagramSubscribe on YouTubeGet the Edifi AppDownload for iPhoneDownload for AndroidSubscribe to Our NewsletterSubscribe to the Freedom Post, delivered every Monday and ThursdayClick here to get the top headlines delivered to your inbox every morning!Links to the NewsBoulder terror attack suspect used flamethrower, set 8 on fire | U.S.Truett McConnell University responds to abuse allegations | EducationTrump envoy 'didn't know' fired Kennedy Center official: source | PoliticsPro-life groups celebrate Vermont amending 'discriminatory' law | U.S.Sesame Street stokes backlash for promoting pride month | Entertainment5 important SBC Annual Meeting proposed resolutions | Church & MinistriesBrandon Lake sweeps K-LOVE Fan Awards | Entertainment

Segment 1: • The Southern Baptist Convention heads to Dallas—and tensions are rising. • Debates over the ERLC's purpose and women's roles in the church resurface. • Millions of dollars are at stake—are they fueling mission or bureaucracy? Segment 2: • Todd questions if the SBC is investing more in politics than people. • Al Mohler even questions the ERLC's effectiveness—so what now? • What if those dollars were redirected to direct gospel work? Segment 3: • The SBC wants unity—but disagreements over essentials threaten that goal. • True unity can't be built on compromise—it must be rooted in truth. • The Lord's Table reminds us: sin is deep, but grace is deeper. Segment 4: • As the SBC meets, deeper questions loom: Are we majoring in minors? • MacArthur and Sproul once showed how to disagree without dividing. • Maybe it's time to refocus on the gospel and rediscover love for God. ___ Thanks for listening! Wretched Radio would not be possible without the financial support of our Gospel Partners. If you would like to support Wretched Radio we would be extremely grateful. VISIT https://fortisinstitute.org/donate/ If you are already a Gospel Partner we couldn't be more thankful for you if we tried!

Last week in Phoenix, Arizona, the Consortium of Multiple Sclerosis Centers (CMSC) held its annual meeting, and we had a chance to talk with some of the top MS experts in the world. Welcome to Part One of our coverage!   First, you'll hear Dr. Kathy Zackowski, the National MS Society's Associate Vice-President of Research, share her overview of the sessions and presentations that especially stood out to her.   Then, you'll hear Dr. Stephen Krieger as he expands on one of the most interesting and provocative presentations at the conference. Dr. Krieger headed up a panel of experts that explained how the terms used to describe MS today (relapsing-remitting, secondary progressive, and primary progressive) are no longer adequate and then offered answers to the question, "If MS is one disease, what does that mean for clinical conversations?".  We have a lot to talk about! Are you ready for RealTalk MS??! This Week: From the 2025 Consortium of MS Centers Annual Meeting  :22 Dr. Kathy Zackowski shares an overview of the sessions and presentations that caught her eye  1:08 Dr. Stephen Krieger discusses seeing MS as one disease  17:11 Share this episode  31:58 Have you downloaded the free RealTalk MS app?  32:18 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/405 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 405 Guests: Dr. Kathy Zackowski and Dr. Stephen Krieger Privacy Policy

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Salman Ali, CEO and Co-Founder of Kouper Health. He shares how Kouper is using generative AI to streamline care transitions, reduce readmissions, and improve follow-up rates—offering actionable insights on implementation, integration, and ROI for health system leaders.This episode is sponsored by Kouper Health.

JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Thomas Stinchcombe discuss the ASCO 2025 Simultaneous Publication paper "Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non-Small-Cell Lung Cancer." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Ece Cali: Hello, and welcome to our 2025 ASCO Annual Meeting series, where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Ece Cali, JCO Editorial Fellow, and I am joined by JCO Associate Editor, Dr. Tom Stinchcombe. In this episode, we will discuss the Journal of Clinical Oncology article and abstract presentation "Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small-Cell Lung Cancer.” NeoADAURA is a randomized global phase III study investigating the efficacy of neoadjuvant osimertinib-containing regimens in patients with resectable EGFR-mutated stage II to IIIB non–small-cell lung cancer. 358 patients were randomized 1:1:1 to receive osimertinib plus chemotherapy, osimertinib monotherapy, or placebo plus chemotherapy in the neoadjuvant setting. The primary endpoint was major pathological response. Osimertinib plus chemotherapy and osimertinib alone demonstrated MPR rates of 26% and 25%, respectively, compared to 2% in the chemotherapy plus placebo arm with a p-value of less than 0.001. Tom, can you please explain to our listeners how you interpret this data? Dr. Thomas Stinchcombe: Great question. Yeah, I think to give a little context, obviously, chemotherapy and immunotherapies preoperatively is becoming the standard of care. However, patients with EGFR-mutant lung cancer generally have not responded to immunotherapy, and many of the trials excluded patients with known EGFR mutation. There have been smaller phase II trials that had looked at EGFR TKIs preoperatively, but none of these were definitive. So I think that this trial is a big trial, and I think some of the strengths are that it has osimertinib alone and chemotherapy with osimertinib arms as compared to the standard of chemotherapy. I think it's going to be really interesting at the meeting to see how this is discussed by the discussant and also what the reaction is to its public presentation. And I think that's largely because there's an alternative paradigm now, surgical resection adjuvant osimertinib, that's available to patients. So I think this will be interesting to see what the reaction is to the induction therapy. For patients with known N2 disease, I've generally given some form of induction therapy prior to surgical resection. So I think that's the subgroup of patients that I'm most likely to employ this approach with based on the results. Dr. Ece Cali: So, in this trial, more than 90% of the patients on the osimertinib-containing regimens underwent curative-intent surgery. So, this speaks to the feasibility of the approach, and the higher MPR rate with osimertinib-containing regimens is encouraging. Event-free survival data is currently immature. You have already touched upon some of the strengths of the trial, but what are the weaknesses and the strengths of this trial? Dr. Thomas Stinchcombe: So, I mean, I think there are some weaknesses. A major pathological response was chosen as an endpoint, and there could be an argument that path CR is more of a prognostic marker. However, the rates of path CR are relatively low, so it would have been very hard to design a trial such as that. And then I think the trial started off as a preoperative trial but effectively became a perioperative trial with preoperative EGFR-TKI, postoperative osimertinib. And so I think it's going to be very hard to determine what the contribution of the components are. And then you've hit on another part that I think is very important when we interpret the data that the maturity on the event-free survival is only 15%, and most people are still on therapy. So the event-free survival, which is an important endpoint, is very immature right now. Dr. Ece Cali: And this trial was designed to compare the neoadjuvant approaches, hence the comparator arm here is neoadjuvant chemotherapy followed by surgery. So, considering the ADAURA trial results with upfront surgery followed by osimertinib as adjuvant, so how do you see this trial's impact on the current clinical practice? Dr. Thomas Stinchcombe: Well, very good question, I think one that we're still struggling with as we kind of look at this data. I think, for me, stage II patients will most likely go to surgery and then get adjuvant osimertinib, and then maybe the N2 patients will get an osimertinib-containing regimen as an induction therapy. I think one of the questions is does it really matter when you get the osimertinib as long as you get it at some point? And I think that's going to be the critical interpretation of some of the data at this point. Dr. Ece Cali: And how do you think this trial shapes the future research for patients with resectable EGFR-mutated lung cancer? Dr. Thomas Stinchcombe: Well, I mean, I think it shows that chemotherapy was really modestly active with an MPR rate of 2%, no pathological responses. And then I think you're going to have to look at an osimertinib plus another targeted therapy component. I think, you know, when I looked at the osimertinib versus the chemo-osimertinib arm, I also was sort of surprised that the MPR rate and the path CR rate were very, very similar. So I think that the question is would a double targeted therapy approach or some other approach matter? And I think it also sets a safety standard. And you touched on this in your comments, that there was not a disparity in terms of the rate of going to surgery or R0/R1 resections. So patients were not having progressive disease events or toxicities that prevented surgery. So I think it does give us good safety data. Dr. Ece Cali: Tom, thank you so much for sharing your insights on the JCO article, "Neoadjuvant Osimertinib for Resectable EGFR-Mutated Non–Small-Cell Lung Cancer." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting, and please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

Editors of CMI Comms, Josh Davis, Erin McCreary and Emily McDonald return for round 2 taking turns to summarise and discuss late-breaker trials presented at ESCMID Global 2025 in Vienna, and whether or not these trials should change your practice. Part 2 covers the ALABAMA trial exploring the safety of penicillin-allergy delabelling using the penicillin allergy assessment pathway, the SOLARIO trial investigating short (≤7 days!) versus long (≥4 weeks) antibiotic courses for orthopaedic infections, the EAGLE-1 trial assessing oral gepotidacin for gonorrhoea, a randomised clinical trial (RCT) from Thailand on oral fosfomycin as carbapenem-sparing, de-escalating therapy in complicated UTIs, and a double-blind RCT from Israel comparing neutralising plasma to placebo for West Nile fever.    This episode was peer reviewed by Dr. Emanuele Rando of Hospital Universitario Virgen Macarena, Seville, Spain and is the second of this two-part series covering selected clinical trials presented at ESCMID Global 2025.  Late-breaker trialsSandoe J, et al. Penicillin allergy assessment pathway versus usual clinical care for primary care patients with a penicillin allergy record to assess safety, de-labelling and antibiotic prescribing: The ALABAMA randomised controlled trialAngkanavisan K, et al. Oral fosfomycin after carbapenems as de-escalating therapy in complicated urinary tract infection: A randomisedcontrolled trialCanetti M, et al. Neutralising plasma versus placebo for hospitalised patients with West Nile fever: a double-blind randomised controlled trialDudareva M, et al. Short or long antibiotic regimes in orthopaedics: the SOLARIO multicentre randomised controlled trialWilson, J. Phase 3 randomised trial of oral gepotidacin for the treatment of uncomplicated gonorrhoea (EAGLE-1) ReferencesIDSA. Public Comment: IDSA Guideline on Management and Treatment of Complicated Urinary Tract Infections; 19 Feb - 19 March 2025.Mostashari F, et al. Epidemic West Nile encephalitis, New York, 1999. Lancet. 2001. doi: 10.1016/S0140-6736(01)05480-0Angus DC. Optimizing the Trade-off Between Learning and Doing in a Pandemic. JAMA. 2020. doi: 10.1001/jama.2020.4984Dudareva M. In: The 42nd Annual Meeting of the European Bone & Joint Infection Society. Barcelona, Spain: 26-28 Sept 2024. Li HK, et al. Oral versus Intravenous Antibiotics for Bone and Joint Infection (OVIVA). NEJM. 2019 doi: 10.1056/NEJMoa1710926

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Quanna Batiste, Vice President, Patient Care Services and Chief Nursing Officer at Touro Infirmary, LCMC Health. Quanna shares insights on optimizing nursing structures, leading with transparency, and embracing innovations like virtual nursing and AI to drive clinical efficiency and future-ready care.

JCO Editorial Fellow Dr. Peter Li and JCO Associate Editor Dr. Andrew Ko discuss the ASCO 25 Simultaneous Publication paper "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, everyone, and welcome to our 2025 ASCO Annual Meeting Series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, JCO Editorial Fellow, and I'm joined by Dr. Andrew Ko, JCO Associate Editor, to discuss the Journal of Clinical Oncology article and abstract presentation "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Now, let's start off with the relevance of this article. Andrew, can you please explain this to our listeners? Dr. Andrew Ko: Sure. Thanks, Peter. So, this was a very large international study evaluating the combination of lenvatinib and pembrolizumab. And just for context, that combination has been approved for use in other solid tumor types. It's FDA approved for renal cell carcinoma, for example, and endometrial carcinoma. But this study was looking specifically at this combination together with a chemotherapy backbone - so either FOLFOX or CAPOX - and comparing that to what at the time was a standard of care, which was just standard chemotherapy by itself. So, this very large study was intending to look at this particular novel combination. And we can get into some of the nuances of this study because the way that the experimental, the combination arm, was designed was perhaps a little bit more on the unusual side and led to maybe some imbalance in terms of how we think about the respective arms. Dr. Peter Li: Okay. We can definitely talk more about that as we go on. So, what are some of the key results of this study, and how do you think this will impact practice in the future? Dr. Andrew Ko: That's a good question. Technically, it was not a positive study. Well, it was positive in the sense that the co-primary endpoints - which included both progression-free survival and overall survival - so, progression-free survival, it did technically meet its endpoint, both in terms of the overall population and the preplanned subgroup analysis of patients who had a PD-L1 CPS of greater than or equal to 1. So, there was a PFS benefit with the experimental combination - the lenvatinib, pembrolizumab, plus chemotherapy - compared to chemotherapy alone. I will say the benefit was on the more modest side. So, if you even look at the medians, it was not a marked difference. If you look at the hazard ratios, they did meet statistical significance. On the other hand, this did not translate into a benefit for overall survival. So, when you ask, "Well, is this going to inform practice?" I'd have to say no. It highlights, I think, that JCO does want to publish articles that aren't necessarily going to be practice-changing, but that I think offer a lot of insights into trial design and important aspects of investigating novel treatments, even if they don't end up moving the needle in routine clinical practice. Dr. Peter Li: I totally agree with you. I mean, it was significant in terms of progression-free survival, but again, not clinically significant. And then overall survival, the interventional arm actually appeared to do slightly worse overall. Can you make some comments on the strengths and the weaknesses of this study, and where do you see us going from here? Dr. Andrew Ko: So, I think a couple of things worth highlighting in this study, very well designed, more than 800 patients in total. So, first of all, as I mentioned at the beginning, the combination was a little bit unique in terms of patients enrolled to the experimental arm got the combination of lenvatinib, pembrolizumab, together with chemotherapy for a very finite duration. So, that period of chemotherapy they received was only three months. And per protocol, patients then just segued to, quote unquote “maintenance treatment” with just the lenvatinib and pembrolizumab combination. Whereas patients on the control arm, meaning chemotherapy alone, would continue chemotherapy basically in perpetuity until their disease progressed or intolerable toxicity. So, there really was an imbalance in terms of, if you think that chemotherapy or continuing chemotherapy beyond that initial three-month period of time may be significant, that could have had some impact on the robustness or the efficacy of the experimental arm. There were some other aspects in terms of perhaps some differences in the rates of post-progression treatment, in other words, patients going on to receive second-line treatment. I think the other very relevant aspect, Peter, in this study was that the control arm - and no fault of the investigators - but the control arm at the time the study was ongoing just consisted of chemotherapy, FOLFOX CAPOX, by itself, without an immune checkpoint inhibitor, right? And we clearly know, based on results of several large phase III studies, and it's now in standard clinical practice, that we routinely use chemotherapy plus an immune checkpoint inhibitor. Certainly for patients with CPS PD-1/PD-L1 scores that are, well, you could argue greater than 1, or perhaps greater than 5 or 10. But the point being that the control arm of the study probably doesn't reflect what is currently used in clinical practice. And that's just always a challenge in clinical trial design, right? That when a study is designed and when it rolls out, you're always at risk in a rapidly changing and moving field that the standard of care may evolve during the lifetime of that particular trial, which is what I think you see in LEAP-015. Dr. Peter Li: Totally understand. And the survival we see from this study is also roughly similar to the combination of immuno-chemotherapy that is the standard of care today, which is, the authors mentioned, 12 to 14 months. Thank you so much, Andrew, for your input and for speaking about the JCO article "Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III Randomized LEAP-015 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

JCO Editorial Fellow Dr. Lauren Shih and JCO Associate Editor Dr. Stephanie Wheeler discuss the ASCO 25 Simultaneous Publication paper "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Lauren Shih: Hello, and welcome to our 2025 ASCO annual meeting series where we cover some of the top JCO papers published simultaneously with their abstract presentations at this year's meeting. I'm your host, Dr. Lauren Shih, JCO editorial fellow, and I'm joined by JCO Associate Editor Dr. Stephanie Wheeler to discuss the Journal of Clinical Oncology article and abstract presentation "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." Let's start with the relevance of the article. Dr. Wheeler, can you explain this to our listeners? Dr. Stephanie Wheeler: Thank you so much. Let's get right into it. So this article is really about understanding different types of Medicare plans and what we should expect to see in terms of their use of low-value treatments for cancer patients. So, as Medicare really is focused on trying to limit the use of low-value cancer treatments, we really need to better understand the drivers of variability. So we know that many cancer patients have multiple treatment options available to them. We also know that the vast majority of older adults beyond age 65 are insured by Medicare, and about half of them are on Medicare Advantage plans, which are serviced by private insurance. And private insurance companies in this case are receiving capitated payments for Medicare beneficiaries to manage their service utilization and reduce costs. So, with respect to Medicare Advantage versus the traditional fee-for-service Medicare, it's not really been known to what extent low-value treatments are differentially used by these types of plans for cancer patients. And so that was really the focus of this article. What the authors found is that across six different types of treatments, in general, the folks who were enrolled in Medicare Advantage plans had reduced use of low-value treatment. So that's a good sign for Medicare beneficiaries. And although the relative difference in that use was somewhat low, this translates to a significant number of Medicare enrollees across the country not receiving these low-value treatments. And of course, this translates to considerable savings at the society level. Dr. Lauren Shih: Are there any additional key results that we should review? Dr. Stephanie Wheeler: Yeah. So I'll tell you just a little bit more about the methods and also their findings. So they looked at six different low-value treatments, and this was in, again, 100% of national Medicare enrollees from 2015 through 2021. So the six low-value treatments that they examined were the use of G-CSFs among patients receiving low-risk chemotherapy and denosumab for those who had castration-sensitive prostate cancer. Then they also looked at four high-cost treatments, including using nab-paclitaxel instead of paclitaxel for patients with breast or lung cancer; second, adding bevacizumab to carboplatin plus paclitaxel for ovarian cancer; third, using brand-name drugs instead of generics when generics were available; and fourth, using biologics instead of biosimilars when biosimilars were available. And these are all, by the way, non-recommended treatments according to a variety of guidelines, including NCCN and ASCO's Choosing Wisely guidelines. So they used the Medicare claims data to examine use of these regimens. They also analyzed results by type of Medicare Advantage plan, whether people were enrolled in a health maintenance organization plan, or an HMO, or a preferred provider organization plan, or a PPO. They also looked at the largest Medicare Advantage insurers—including Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealth—and limited their analyses to those that had complete encounter data. And what they found across the board is that the enrollees in Medicare Advantage plans generally had lower use of these low-value treatments. And the largest differences between Medicare Advantage and traditional Medicare plans were in the outcomes, including G-CSF use and using denosumab for castration-resistant prostate cancer, and then the combination of bevacizumab, carboplatin, and paclitaxel versus carboplatin and paclitaxel. And all of these had a change in use ranging from about 19% change to 24% change in use. This is significant as a field as we look at ways in which different plan organization can influence use of treatments, particularly given the excess cost of cancer care. This is something we really want to pay attention to. So I'd encourage folks to look more closely at the results by treatment type as well as the results by plan type to see a little bit more about what was going on across different plan types. Dr. Lauren Shih: Great. And are there any outstanding questions that need to be answered? Dr. Stephanie Wheeler: Yes, there always are, of course. I think the study has several strengths that are worth noting. First, they have 100% of Medicare enrollees, so there's national coverage there, which is, you know, quite outstanding. They also use an appropriate choice of analysis to help deal with some of the selection. So they use inverse probability of treatment weights, and they control for practice and county indicators to try to get some realistic adjustment for the selection that happens in terms of how patients are enrolled in different Medicare Advantage versus traditional fee-for-Medicare plans. These statistical approaches are a good idea, but they are limited by the observed variables that we can use for these kinds of adjustments. And so any unobserved—confounding or any unobserved factors that would influence selection in these plans aren't going to be captured well. So preferences, for example, that patients may have about different types of plans when they're insuring themselves and their families may not be captured. Second, the data that are used are only encounter data from those plans with complete records. That may mean that smaller Medicare Advantage insurers or those that don't have as comprehensive records are not included. So this may not be reflective of their practice patterns. And then third, of course, this only looked at six different low-value cancer treatments. It remains to be seen whether this kind of finding extends to other types of low-value cancer treatments, and that's an opportunity for future study. Finally, I would say that we don't exactly know why these patterns exist. It could be that Medicare Advantage plans have different approaches to prior authorization. They could have more in-house quality control and management to really understand, among their population for whom they're receiving Medicare Advantage payments, to really look at care quality and assess Choosing Wisely guidelines. We don't know exactly how that's playing out. And so we need additional data to really figure out what's working here and what are opportunities for future policy and payment innovations that can further reduce low-value care. Dr. Lauren Shih: Great. Thank you so much, Dr. Wheeler, for speaking to us about the JCO article, "Use of Low-Value Cancer Treatments in Medicare Advantage Versus Traditional Medicare." We really appreciate your insights. Dr. Stephanie Wheeler: Thanks for having me. Dr. Lauren Shih: Join us again for the latest simultaneous publications from the ASCO 2025 Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

JCO Editorial Fellow Dr. Ece Cali Daylan and JCO Associate Editor Dr. Grant McArthur discuss the ASCO 2025 Simultaneous Publication paper "A Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab vs. Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma (cSCC)." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Ece Cali: Hello, and welcome to our 2025 ASCO Annual Meeting series where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Ece Cali, and I'm joined by JCO Associate Editor Dr. Grant McArthur. Today, we will discuss Journal of Clinical Oncology article and abstract presentation "A Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma." Let's start with a brief overview of the clinical trial. This is a randomized phase II trial that compared avelumab plus cetuximab to avelumab in PD-1/PD-L1 antibody-naive patients with advanced cutaneous squamous cell carcinoma. This is a cooperative group study conducted in the United States. Sixty patients were randomized one-to-one and stratified by PD-L1 and HIV status. The primary endpoint was progression-free survival. Patients on the cetuximab plus avelumab arm had a median PFS of 11.1 months, while patients on the avelumab arm had a median PFS of 3 months, corresponding to a hazard ratio of 0.48 with a p-value of 0.018. Grade III or higher treatment-related adverse events occurred in 48% of the patients on the combination arm versus 21% of patients on the avelumab arm. Dr. McArthur, can you please explain to our listeners how you interpret this data? Dr. Grant McArthur: These results are very important because they provide proof of concept for inhibiting PD-L1 as a target when combined with EGFR, so inhibiting PD-L1 with avelumab and inhibiting EGFR with cetuximab, in a randomized trial with a very significant impact in terms of efficacy. So, what this does is it provides proof of concept for inhibiting those targets in cutaneous squamous cell carcinoma of the skin. Avelumab is not approved for cutaneous squamous cell carcinoma of the skin, and so further studies would need to be done, particularly asking the question about combination with the approved PD-1 agents cemiplimab and pembrolizumab. Dr. Ece Cali: I still find the difference in median PFS with various PD-1/PD-L1 inhibitors striking in this context. In this trial, avelumab, as you mentioned, the PD-L1 inhibitor, demonstrated a median PFS of 3 months, whereas PD-1 inhibitors cemiplimab and pembrolizumab have demonstrated longer median PFS in other trials. So, what are some potential reasons for this, and do you think this difference impacts the interpretation of the results here? Dr. Grant McArthur: So, the obvious reason for the differences is that avelumab targets PD-L1, where pembrolizumab and cemiplimab inhibit PD-1, so there could be simply a difference in the target to explain those differences in progression-free survival. However, as you point out, cross-trial comparisons, one has to do with caution because you can, in different phase II studies, enroll different patient populations, which would impact the progression-free survival. So, we have to be cautious about that interpretation. However, given that cemiplimab and pembrolizumab are the approved agents, I think they are the logical ones for further clinical development. Nonetheless, this is still a very important proof-of-concept trial showing that there is a strong clinical signal when you combine EGFR inhibition with inhibition of PD-L1 versus PD-L1 alone. Dr. Ece Cali: I want to highlight some of the safety data presented in this trial as well. The treatment discontinuation rate due to adverse events was much higher in the combination arm, reaching 31% compared to the 14% in the single-agent avelumab arm. The most common grade III adverse events were infusion reaction, rash, and diarrhea in the combination arm. So, these adverse events may affect patients' quality of life significantly. So, what are your thoughts on this, Dr. McArthur? Dr. Grant McArthur: So, the safety data is important. What we're seeing is safety related to each individual agent. So, we have diarrhea and skin rash from the cetuximab, and the infusion reactions is a common toxicity of avelumab. I think what's important, given this is proof of concept inhibiting these targets going forward to further studies, is that agents such as cemiplimab and pembrolizumab have a very low infusion reaction rate. So, the treatment discontinuations due to infusion reaction are unlikely to be an issue with cemiplimab and pembrolizumab when further clinical trials are done. Of course, there is still the issue of diarrhea and skin rash. Now, that can be managed in many patients with EGFR inhibition, you know. However, one would have to await safety data from a significant patient cohort with a combination of cetuximab with either cemiplimab or pembrolizumab, of course, to assess the clinical impact of those safety signals. But I would expect there to be definitely rash and diarrhea as predominant toxicities with those other combinations as well. Dr. Ece Cali: And lastly, I think we touched upon this a little bit, but how do you think this trial impacts the clinical practice, and what are some outstanding questions that need to be addressed in this field in light of the data from this trial? Dr. Grant McArthur: So, the most important outstanding question is - of course, we've already alluded to in our conversation - regarding using anti-PD-1 agents such as pembrolizumab or cemiplimab. So, that needs to be undertaken. Clearly, a randomized trial would be required combining cetuximab with those agents because they are quite active as single agents with impressive response rates and PFS. So, that is the way forward. There's other important clinical questions as well, though. So, patients that get locally aggressive or metastatic cutaneous squamous cell carcinoma of the skin are often immunosuppressed. And so, we do need data in patients that are immunosuppressed, either due to treatment of immune-related disorders - and also organ transplantation. We see a lot of cutaneous squamous cell carcinoma in organ transplant patients. So, these are important patient subsets that would also need to be investigated in further clinical development. However, overall, you know, this is a strong signal, hazard ratio of less than 0.5, and very worthy of further investigation in randomized trials of inhibiting these targets. Dr. Ece Cali: This was a great discussion. Thank you so much for your insight, Dr. McArthur, for speaking about the JCO article "A Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

JCO Editorial Fellow Peter Li and JCO Associate Editor Eileen O'Reilly discuss the ASCO 25 Simultaneous Publication paper "Tumor-Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Peter Li: Hello, and welcome to our 2025 ASCO Annual Meeting series, where we cover some of the top JCO papers published simultaneously with their abstract presentation at this year's meeting. I'm your host, Dr. Peter Li, and I'm joined by JCO Associate Editor Dr. Eileen O'Reilly to discuss the Journal of Clinical Oncology article and abstract presentation "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Now, let's start with the relevance of the article. Eileen, can you explain this study to our listeners? Dr. Eileen O'Reilly: Thanks very much, Peter, for the invitation today to discuss this. Yes, so this is a positive phase 3 trial that was conducted in locally advanced, unresectable pancreas cancer. Patients were randomized to receive either gemcitabine and nab-paclitaxel, international standard, with or without tumor-treating fields. And this is a device like a battery pack that you would wear with a goal to wear that approximately 18 hours a day. And the primary endpoint of this study was overall survival, with key secondary endpoints of tumor response, progression-free survival, looking at pain-free survival, and distant progression-free survival. So, the primary endpoint was met with a median overall survival of 16.2 months compared to 14.2 months on the intervention versus control arm, with a hazard ratio of 0.82. And so that met the pre-specified boundary. There was not an increase in progression-free survival, but there was an increase in control of pain on the tumor-treating fields study. So, it was a large, global study, community, academic sites, randomized 570 people, and it supports what I think we've seen in other difficult-to-treat malignancies using tumor-treating fields, that there's a signal of interest. Dr. Peter Li: Can you speak to some of the strengths and weaknesses of this study? Dr. Eileen O'Reilly: So, strengths: it was a large study. It included community sites, it included academic sites. It included ECOG performance status 0, 1, and some patients with 2. The intent was locally advanced. It probably is fair to say that there were some patients who had more advanced disease based on early progression, based on relatively high CA 19-9 for a percentage of people. But likely that was, with random assignment, that would have presumably fallen out between the arms. The inclusion of patients with a lower performance status is nice to see in large phase 3 studies in pancreas cancer. So, they would be some of the strengths. So maybe some of the limitations are the fact that it's an open-label study - so, always some biases inherent in that. Acknowledging that the primary endpoint was overall survival, presumably that wouldn't be directly influenced by that. And there was an imbalance of women on the control arm, and women do fare a little better in this disease, so possibly kind of weighted one of the study arms a little bit. But nonetheless, I think it was a rigorously designed and rigorously conducted phase 3 trial. It's always hard to fully interpret the signal in locally advanced disease because of the fact that some patients go on to surgery, some patients have a treatment switch of cytotoxic therapy, some patients will go on to radiation. And the endpoint here of overall survival, to a degree, eliminates some of that. So, the benchmark, I think, was generally high here. Dr. Peter Li: Gotcha. And then with these findings and this positive study, how do you foresee this research being implemented and how it will impact clinical practice moving forward? Dr. Eileen O'Reilly: I think there'll be an educational need to introduce this approach to the community and to the pancreas cancer world. Again, there's a precedent in glioblastoma and data from other diseases, so there's some familiarity with this. I think people always want to understand how it works and why it works, and that's something that we'll look forward to hearing more about mechanistically, and also seeing how it can be built upon. And there's some intriguing data with the combination of tumor-treating fields and immunotherapy that's being evaluated in the PANOVA-4 study. So, we'll stay tuned to hear how that reads out in due course. But I think overall, it'll be educational and learning, managing the cutaneous impacts or some skin irritation effects from this, and building on this signal in locally advanced disease. Dr. Peter Li: Well, thank you so much, Eileen, for your time and for speaking about the JCO article, "Tumor Treating Fields with Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal, Phase 3 PANOVA-3 Study." Join us again for the latest simultaneous publications from the 2025 ASCO Annual Meeting. Please take a moment to rate, review, and subscribe to all ASCO podcast shows at asco.org/podcasts. Until then, enjoy the rest of ASCO 2025. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Scott Polenz, Advisory Services Principal Consultant at CHG Healthcare. Scott shares insights on physician and APP recruitment and retention, emphasizing the importance of strategic planning, flexibility, and personalizing the candidate experience to address today's workforce challenges.This episode is sponsored by CHG Healthcare.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Sumit Sachdeva, President of Omega Healthcare. He shares how Omega Healthcare is transforming the healthcare landscape by building an empowered ecosystem, leveraging AI and technology to address financial pressures, clinician burnout, and the patient experience across care settings. This episode is sponsored by Omega Healthcare.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Andrew Molosky, President and CEO, Chapters Health System. Andrew shares how his organization is transforming end-of-life and chronic illness care through value-based design, workforce-first leadership, and a data-driven approach to employee engagement and retention.

Featuring a slide presentation and related discussion from Dr Rafael Fonseca, including the following topics: Recent updates from ASH 2024 on the up-front use of anti-CD38 monoclonal antibodies for multiple myeloma (MM) (0:00) Updated data with belantamab mafodotin for the management of MM (12:39) Updated findings with chimeric antigen receptor T cell therapy for the management of MM (17:52) ASH 2024 updates with other novel agents and strategies for the management of MM (21:32) CME information and select publications

Featuring an interview with Dr Rafael Fonseca, including the following topics: Safe management of bispecific antibodies and chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma (MM) (0:00) Sequencing bispecific antibodies and CAR T-cell therapy (10:40) Available data with and potential future clinical integration of belantamab mafodotin in the management of MM (16:03) Optimizing maintenance therapy for patients with MM (31:11) Novel management strategies for smoldering myeloma (36:29) Role of anti-CD38 antibodies in the up-front management of MM (41:41) Available data with cereblon E3 ligase modulatory drugs for MM (47:45) CME information and select publications

Mike and Charlie recapped the early buzz from the SEC's annual meetings. The guys interviewed Greg Cosell, a senior producer for NFL Films, and Glenn Guilbeau, a columnist for TigerRag.com. Cosell evaluated the Saints' 2025 rookie class, highlighting LT Kelvin Banks Jr., QB Tyler Shough, and RB Devin Neal. Mark Cook, an NBA scout, joined Sports Talk to discuss the Eastern and Western Conference Finals. Mike, Charlie, and Steve played their daily "Triple Option" segment. Steve and Charlie broke down LSU head coach Jay Johnson's options for the upcoming Baton Rouge regional. The guys spoke to John Hendrix, a Saints beat reporter for NewOrleans.Football, about the Saints' new-look offensive line, cornerback depth, wide receiver group, and running back room. Steve and Charlie reviewed ESPN's brutal FPI projection for the Saints ahead of the 2025 season. Joe Healy, a reporter for D1Baseball.com, previewed the NCAA Baseball Tournament, highlighting the Baton Rouge regional, the under-seeded hosts, and the teams on upset alert this weekend.

Dr Rafael Fonseca from Mayo Clinic in Phoenix, Arizona, discusses datasets from the 2024 ASH meeting on the management of newly diagnosed and relapsed/refractory multiple myeloma. CME information and select publications here.

Ralph Rocco, Willis Brucker, Paolo Vicinelli break down PMV with a Catalyst and Financial Engineering through M&A at the 2025 GAMCO Annual Meeting.To learn more about Gabelli Funds' fundamental, research-driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com.Connect with Gabelli Funds:• X - https://x.com/InvestGabelli• Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/investgabelli/ http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)

1992 Heisman Trophy winner Gino Torretta, Chris Marangi (Co-CIO, Value), and Mike Galatioto discuss opportunities to invest directly in sports and sports franchises.To learn more about Gabelli Funds' fundamental, research-driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com.Connect with Gabelli Funds:• X - https://x.com/InvestGabelli• Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/investgabelli/ http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)

Mario Gabelli (Founder and CEO) offers his outlook on the economy, inflation, tariffs, and taxes at the 2025 Gabelli Annual Meeting.To learn more about Gabelli Funds' fundamental, research-driven approach to investing, visit https://m.gabelli.com/gtv_cu or email invest@gabelli.com.Connect with Gabelli Funds:• X - https://x.com/InvestGabelli• Instagram - https://www.instagram.com/investgabelli/ • Facebook - https://www.facebook.com/InvestGabelli • LinkedIn - https://www.linkedin.com/company/investgabelli/ http://www.Gabelli.com Invest with Us 1-800-GABELLI (800-422-3554)

Andy and Randy talk about Greg Sankey's comments at the SEC's Annual Meetings and how he's not the guy to lead College Football into the next era.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Megan Harkins, Director of Compliance at Innovaccer, and Sumaya Noush, Partner at McDermott Will & Emery. They explore the rapidly evolving intersection of AI, healthcare, and law—discussing risk, regulation, global frameworks, and the essential role of compliance as a strategic business partner.This episode is sponsored by McDermott Will & Emery.

Laura Remmerde, from Haines, Oregon, USAJoin us at this year's Annual Meeting of the Mother Church. Find out more at christianscience.com/annualmeeting.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Sean Fadale, President and Chief Executive Officer, Nathan Littauer Hospital and Nursing Home. Sean shares how standardizing workflows, improving data transparency, and focusing on leadership fundamentals are helping his rural organization improve outcomes, boost staff engagement, and navigate healthcare's growing uncertainty.

Featuring an interview with Dr Lindsey Roeker, including the following topics: Clinical development of novel Bruton tyrosine kinase (BTK) degraders in therapy for chronic lymphocytic leukemia (CLL) (0:00) Safety of BTK inhibitors in older and frail patients with CLL (3:41) Utility of minimal residual disease-guided treatment with venetoclax/obinutuzumab (9:20) Impact of the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab in CLL (16:32) Utility of acalabrutinib, venetoclax and obinutuzumab for high-risk CLL (23:31) Emerging data with sonrotoclax and zanubrutinib in treatment-naïve CLL (25:16) Sequencing, tolerability and future development involving pirtobrutinib (25:57) Emerging data with the addition of a BTK inhibitor to chimeric antigen receptor T-cell therapy (32:28) Clinical considerations in the management of Richter's transformation (38:14) Survival outcomes and quality of life for patients with CLL (41:02) Ongoing and future efforts to improve CLL treatment outcomes (45:01) CME information and select publications  

Dr Lindsey Roeker from Mayo Clinic in Rochester, Minnesota, discusses recent updates on available and novel treatment strategies for chronic lymphocytic leukemia. CME information and select publications here.

Featuring a slide presentation and related discussion from Dr Lindsey Roeker, including the following topics: Recent clinical updates with standard regimens for chronic lymphocytic leukemia (CLL) (0:00) Utility of minimal residual disease-guided treatment intensification after ibrutinib with venetoclax  (7:03) Major long-term findings from the GLOW study of ibrutinib with venetoclax (10:35) Principal findings from the AMPLIFY study of acalabrutinib with venetoclax with or without obinutuzumab (12:28) Findings with combined acalabrutinib, venetoclax and obinutuzumab for patients with previously untreated high-risk disease  (15:52) Early clinical findings with sonrotoclax and zanubrutinib as front-line treatment for CLL (18:12) Principal findings from the BRUIN CLL-321 trial of pirtobrutinib for patients who previously received a covalent Bruton tyrosine kinase (BTK) inhibitor  (19:38) Emerging evidence with pirtobrutinib, venetoclax and obinutuzumab as front-line treatment  (22:15) Novel strategy combining lisocabtagene maraleucel with ibrutinib for relapsed/refractory (R/R) CLL (24:13) Available data with epcoritamab monotherapy for R/R CLL  (26:58) The emerging pharmacologic class of BTK degraders  (29:04) CME information and select publications

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Kate Neal, IT Director, Access Innovations and CRM at Cleveland Clinic, and Charlie Lougheed, CEO & Founder of Axuall. They discuss the critical role of accurate provider data in patient access, care coordination, and workforce optimization—and how automation and analytics are transforming outdated, manual processes across healthcare.This episode is sponsored by Axuall.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Tiffany Lawrence, President and CEO of Sanford Health Fargo. Tiffany discusses launching one of the nation's first rural hospital-at-home programs, securing Magnet designation for nursing excellence, and tackling rural healthcare workforce shortages through major investments in graduate medical education.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Ianessa Humbert, CEO of The Swallowing Wellness Center. Dr. Humbert shares how her groundbreaking outpatient clinic is revolutionizing care for swallowing disorders, reducing hospital readmissions, and tackling widespread health literacy gaps in a neglected area of healthcare.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Lisa Roy, President and CEO of Optimum Energy. Lisa discusses how healthcare organizations can navigate financial pressures, aging infrastructure, and evolving care models through strategic capital deployment and innovative solutions like Energy as a Service.This episode is sponsored by Optimum Energy.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Maria Ansari, Chief Executive Officer and Executive Director of The Permanente Medical Group; Chief Executive Officer of Mid-Atlantic Permanente Group; and Co-Chief Executive Officer of The Permanente Federation. Dr. Ansari shares how her organization is leveraging AI to reduce clerical burden, tackling the care-demand imbalance with upstream interventions, and reimagining the healthcare workforce through team-based, tech-enabled care.

Mark Unger, CS, from Boise, Idaho, USAYou can read about Mark's healing in the Christian Science Sentinel.Come join us! Register for this year's Annual Meeting, being held June 2nd in person and online.

This episode recorded live at the Becker's Hospital Review 15th Annual Meeting features Dr. Jay Grider, Chief Quality Officer and Chief Executive Officer, Kentucky Medical Services Foundation, University of Kentucky & Kim Adelman, principal, ECG Management Consultants. They discuss how investing in quality and patient safety drives efficiency, cost savings, and long-term sustainability—and why aligning leadership priorities is critical for success.This episode is sponsored by ECG Management Consultants.

This episode, recorded live at the Becker's Hospital Review 15th Annual Meeting, features Dr. Imamu Tomlinson, Chief Executive Officer of Vituity. Dr. Tomlinson shares insights from his book "Less Than One Percent", discussing how authenticity, adversity, and positive disruption can reshape healthcare leadership and unlock untapped potential across organizations.This episode is sponsored by Vituity.

Eric Nelson, CSB, from Petaluma, California, USAYou can read Eric's editorial in the Christian Science Sentinel.Come join us! Register for this year's Annual Meeting, being held June 2nd in person and online.